ArticleMolecular and cellular pediatrics2026
Retrospective screening for congenital cytomegalovirus infection in the Survey of Neonates in Pomerania shows very low disease burden.
Article in Molecular and cellular pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital cytomegalovirus (cCMV) infection is considered one of the most common infectious pathologies in neonates, showing a wide range of clinical manifestations, ranging from completely asymptomatic to critically ill newborns. Primary infection during the first trimester of pregnancy carries the highest risk of severe fetal involvement. However, the majority of infected fetuses show an asymptomatic or mild course of disease. The most common long-term sequela is sensorineural hearing loss, which is detected in only about 50% of affected children during newborn hearing screenings. Furthermore, epidemiological data on disease burden remain limited and show considerable variability. The aim of this study was to investigate the prevalence of cCMV and its associated disease burden at follow-up, particular sensorineural hearing loss, in a population-based birth cohort.
resultsWe conducted a retrospective analysis for cCMV in n = 1995 newborns using urine and plasma biosamples from the second baseline cohort of the Survey of Neonates in Pomerania (SNiP-II). Four participants (prevalence rate 0.2%) were tested positive. Two of these cases had already been identified shortly after birth, having been screened for cCMV due to clinical suspicion. The seroprevalence of IgG antibodies among pregnant women was 47.6%. For follow-up, the patient database of our Department of Otolaryngology, Head and Neck Surgery (ENT) was reviewed for hearing pathologies in all children born during the SNiP-II recruitment period (2013–2017). Twelve out of n = 1138 SNiP-II participants (1.1%) showed confirmed sensorineural hearing loss (SNHL), none of which were associated with cCMV. A complete clinical follow-up of the cCMV-positive cases revealed no sequelae related to the infection.
conclusionsBy using a population-based retrospective analysis approach, we demonstrated a very low prevalence and disease burden of cCMV in our region. Our data supports the current guideline recommendations of a risk factor-based screening strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.